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Abstract
Thiosemicarbazones (TSCs) are an interesting class of ligands that show a diverse range of biological activity, including anti-
fungal, anti-viral and anti-cancer effects. Our previous studies have demonstrated the potent in vivo anti-tumor activity of
novel TSCs and their ability to overcome resistance to clinically used chemotherapeutics. In the current study, 35 novel TSCs
of 6 different classes were designed using a combination of retro-fragments that appear in other TSCs. Additionally, di-
substitution at the terminal N4 atom, which was previously identified to be critical for potent anti-cancer activity, was
preserved through the incorporation of an N4-based piperazine or morpholine ring. The anti-proliferative activity of the
novel TSCs were examined in a variety of cancer and normal cell-types. In particular, compounds 1d and 3c demonstrated
the greatest promise as anti-cancer agents with potent and selective anti-proliferative activity. Structure-activity relationship
studies revealed that the chelators that utilized ‘‘soft’’ donor atoms, such as nitrogen and sulfur, resulted in potent anti-
cancer activity. Indeed, the N,N,S donor atom set was crucial for the formation of redox active iron complexes that were able
to mediate the oxidation of ascorbate. This further highlights the important role of reactive oxygen species generation in
mediating potent anti-cancer activity. Significantly, this study identified the potent and selective anti-cancer activity of 1d
and 3c that warrants further examination.
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Introduction
Iron is an essential element that is necessary for a number of
cellular processes, such as cellular proliferation [1,2,3]. In fact, the
iron-containing enzyme, ribonucleotide redutase, is involved in the
rate-limiting step of DNA synthesis and is responsible for the
conversion of ribonucleotides to their deoxyribonucleotide coun-
terparts [4,5]. Importantly, alterations in the iron metabolism of
cancer cells relative to their normal counterparts have highlighted
the potential of iron chelation therapy to act as a novel treatment
avenue. Cancer cells demonstrate a higher requirement for iron
than normal cells and this is emphasized by the increased
expression of the transferrin receptor 1 (TfR1), that takes up iron
from the iron transport protein, transferrin (Tf), on the cell surface
[6,7,8]. Additionally, the expression of iron-dependent enzyme,
ribonucleotide reductase, is markedly higher in tumor cells than
normal cells [9]. These factors render tumor cells more sensitive to
iron chelation.
Although iron chelators (e.g., desferrioxamine; DFO) have been
clinically utilized for the treatment of iron overload disease [1,3],
novel thiosemicarbazone (TSC) chelators have been widely
investigated as potential anti-cancer agents [10,11,12,13,14,
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15,16,17,18,19,20,21]. Although the molecular mechanisms
involved in the activity of TSCs have not been completely
elucidated, a number of modes of action have been reported
[3,15,21,22,23]. This includes: (1) the inhibition of cellular iron
uptake from Tf [10,13,18]; (2) the mobilization of iron from cells
[10,13,18]; (3) the inhibition of the ribonucleotide reductase
activity [24,25]; (4) the up-regulation of the metastasis suppressor
protein, N-myc downstream regulated gene 1 [26,27,28,29]; and
(5) the formation redox active metal complexes that produce
reactive oxygen species (ROS) [10,15,21,23,30]. This latter
mechanism is significant, especially as studies have demonstrated
the important role of ROS generation in increasing the selective
activity of chelators against tumor cells [10,15,21].
The TSC, 3-aminopyridine-2-carboxaldehyde thiosemicarba-
zone (Triapine; Fig. 1), has been examined in .20 Phase I and II
clinical trials as a novel cancer chemotherapeutic [11,31,32,33,34,
35,36,37,38,39,40,41]. Although clinical trials using Triapine have
generally demonstrated limited anti-tumor activity [36,37,38,40],
other studies have shown positive results in locally advanced
cervical and vaginal cancers when co-administered with cisplatin
and radiochemotherapy [33,34]. Notable side effects observed
upon Triapine administration include methemoglobin formation
and hypoxia [35,39,41] and these problems have necessitated the
development of other more active and selective TSCs with potent
anti-cancer activity.
Several classes of TSCs have been developed as potential anti-
proliferative agents (Fig. 1), a number of which show marked and
selective anti-tumor activity both in vitro [10,15,21,42] and in vivo
[12,21,26,42]. For example, a five day treatment with di-2-
pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT;
Fig. 1) at 0.4 mg/kg in mice reduced the growth of a murine
M109 lung carcinoma to 47% of the control [21]. Additionally,
Dp44mT showed potent and selective anti-tumor activity in vitro
and in vivo against a range of human tumor xenografts [42] and
was able to form redox active metal complexes that generate ROS
[15,21,30]. Although this TSC showed great potential, it
demonstrated cardiac fibrosis at high, non-optimal doses [42].
Thus, further investigations into Dp44mT analogs were necessary
and have resulted in the development of di-2-pyridylketone 4-
cyclohexyl-4-methyl-3-thiosemicarbazone (DpC; Fig. 1) [12,26].
DpC has demonstrated selective in vitro and in vivo anti-tumor
activity by both the intravenous [12,26] and oral routes [12] and is
currently being further evaluated for entrance into clinical trials.
Recently, other TSCs have also been shown to have a novel
application as photodynamic therapy enhancers [43].
We have previously examined a variety of quinolone-based
TSCs that demonstrate in vitro anti-proliferative activity [16]. In
the current investigation, we synthesized 35 novel TSCs of 6
classes that were designed by the combination of active fragments
present in previously reported analogs [16,44]. Earlier studies
indicated that di-substitution at the terminal (N4) nitrogen is
crucial for effective anti-cancer activity [12,21]. In the present
study, we have preserved di-substitution at the N4 atom through
the construction of an N4-based piperazine or morpholine ring, a
fragment that is present in several active TSCs [45,46]. The anti-
proliferative activity and selectivity of these novel TSCs was
examined in vitro against human cancer cell-types and normal
human dermal fibroblast (NHDF) cells. Those series that
demonstrated the ability to form redox active iron complexes
and mediate the oxidation of ascorbate showed potent anti-
proliferative activity, highlighting the importance of ROS gener-
ation in their anti-cancer activity.
Materials and Methods
The reagents were purchased from Sigma-Aldrich (St. Louis,
MO, USA), ACROS Organics (Geel, Belgium) or Princeton
Chemicals Ltd (Luton, Bedfordshire, UK). Silica gel 60 (0.040-
0.063 mm; Merck, Darmstadt, Germany) was used for column
chromatography. Thin layer chromatography (TLC) experiments
were performed on alumina-backed silica gel 40 F254 plates
(Merck). The plates were illuminated under UV (254 nm) and
evaluated in iodine vapor. The melting points were determined on
an Optimelt MPA100 instrument (Stanford Research Systems,
Sunnyvale, CA, USA) and are uncorrected. High resolution-mass
spectrometry (HRMS) analysis was performed for all new
compounds on a Finnigan MAT95 spectrometer (Thermo Fisher
Scientific, Bremen, Germany) or on a Mariner ESI-TOF
spectrometer (Applied Biosystems, Thermo Fisher Scientific).
Figure 1. Chemical structures of the chelators, Triapine, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), di-2-
pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), 2-benzoylpyridine 4,4-dimethyl-3-thiosemicarbazone (Bp44mT)
and quinoline thiosemicarbazone (QT).
doi:10.1371/journal.pone.0110291.g001
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All 1H- and 13C-NMR spectra were recorded on a Bruker AM-
400 spectrometer (399.95 MHz for 1H; 99.99 MHz for 13C;
BrukerBioSpin Corp., Coventry, UK). Chemical shifts are
reported in ppm against the internal standard, Si(CH3)4. Easily
exchangeable signals were omitted when diffuse. Syntheses were
performed on a CEM-DISCOVERY microwave reactor (CEM
Corporation, Matthews, NC, USA) with temperature and pressure
control.
Log Pcalc values were calculated using ChemDraw 12 (Perkin-
Elmer, Waltham, MA, USA) by performing Crippen’s fragmen-
tation [47], Viswanadhan’s fragmentation [48] and Broto’s
method [49] and then calculating the average log Pcalc.
Synthesis of Thiosemicarbazide Precursors (a–f)
General method I. N-alkyl or N-aryl piperazine (6 mmol)
was added to a solution of 1,19-thiocarbonyldiimidazole (6 mmol;
1.068 g) in 25 mL of dichloromethane and the reaction mixture
was stirred for 24 h at room temperature. The organic solvent was
separated and extracted 3 times using water, then dried over
anhydrous magnesium sulfate, filtered and concentrated to
provide the crude piperazine derivatives. These crude products
were used in the next step without further purification. These
intermediates were added to a solution of hydrazine hydrate in
25 mL of ethanol at room temperature. The reaction mixture was
refluxed for 3 h and cooled to obtain a white precipitate which was
collected via filtration as the final product (Fig. 2). All obtained
thiosemicarbazides were crystallized from methanol. See File S1
for structural characterization details and the crystal structure (Fig.
S1 in File S1) and data (Table S1 in File S1) of 4-ethylpiperazine-
1-carbothiohydrazide (a).
General method II. Carbon disulfide (CS2) (0.2 mol,
12.06 mL) was added dropwise over 15 min to N-methylcyclo-
hexylamine (0.2 mol, 26.3 mL) in NaOH solution (0.8 M,
250 mL). The reaction mixture was intensively stirred for
20 min and then sodium chloroacetate (0.2 mol) was added to
the solution and allowed to stir for 15 h. The reaction mixture was
neutralized with concentrated HCl (20 mL) to give the carbox-
ymethylthiocarbamate intermediate as a white precipitate. The
obtained carboxymethylthiocarbamate intermediate (0.08 mol)
was then reacted with hydrazine hydrate (0.08 mol) in water
(10 mL). This reaction mixture was gently refluxed for 2 h to give
white crystals of the thiosemicarbazide (Fig. 3). The final product
was crystalized from methanol-water (1/1, v/v).
Preparation of TSC Derivatives
The heteroaromatic TSC analogs were synthesized by reacting
the respective heteroaromatic ketone or carbaldehyde and
thiosemicarbazide under microwave irradiation. Equimolar quan-
tities of the appropriate thiosemicarbazide (0.5 mmol) and
carbonyl compound (0.5 mmol) were dissolved in 4 mL of EtOH
with the addition of 0.1 mL of acetic acid as catalyst (Fig. 4). The
resulting mixture was heated in a microwave reactor at 83uC/
30 min (max. microwave power 50 W). After cooling, the
precipitated solid was filtered and washed with ether. The final
product was purified using crystallization (from ethanol or
methanol) or column chromatography. See File S1 for structural
characterization details, the crystal structure (Fig. S2 in File S1)
and data (Table S1 in File S1) of Z-N9-(di(pyridin-2-yl)methylene)-
4-(pyridin-2-yl)piperazine-1-carbothiohydrazide (1d) and isosbes-
tic curves (Fig. S3 in File S1).
HPLC Purity Data
The final purity of the TSCs was determined using the following
general conditions: Gynkotek HPLC System (Gynkotek); Pump
T580; Autosampler GINA50 (Gynkotek); Detector DAAD
UVD340U; Column: Hilic Kinetex 100 A˚ (Phenomenex, Tor-
rance, CA, USA); Flow: 0.5 mL/min (0–1 min), 0.5–1.2 mL/min
(1–3 min), 1.2 mL/min (3–7 min), 1.2–0.5 mL/min (7–8 min),
90% CH2Cl2, 10% CH3OH; UV at 250 nm; Software: Chrome-
leon (Thermo Scientific, Waltham, MA, USA). See File S1 for
HPLC purity data (Table S2 in File S1).
Cell Culture
The human cancer cell types (neuroepithelioma (SK-N-MC),
colon cancer (HCT116 with wild-type p53 (p53+/+)), Burkitt’s
lymphoma (Raji) and cervical carcinoma (HeLa)) cells and normal
human dermal fibroblasts (NHDF) were obtained from the
American Type Culture Collection (ATCC, Manassas, VA,
USA). HCT116 null p53 (p532/2) cells were obtained from the
Maria Sklodowska-Curie Memorial Cancer Center and Institute
of Oncology, Poland.
The SK-N-MC cells were cultured in minimum essential
medium (MEM; Life Technologies, Grand Island, New York,
USA) containing 10% (v/v) fetal bovine serum (FBS; Life
Technologies), 1 mM sodium pyruvate (Life Technologies), 1%
(v/v) non-essential amino acids (Life Technologies), 2 mM L-
glutamine (Life Technologies), 100 U/mL penicillin (Life Tech-
nologies), 100 mg/mL streptomycin (Life Technologies) and
Figure 2. Synthetic route to yield thiosemicarbazides, a–e.
doi:10.1371/journal.pone.0110291.g002
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0.28 mg/mL fungizone (Bristol Myers Squibb Pharmaceuticals,
Montreal, Canada). The HCT116 and NHDF cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich)
supplemented with 12% (v/v) heat-inactivated FBS (HCT116;
Life Technologies) or 15% (v/v) FBS (NHDF; Life Technologies),
100 mg/mL of gentamicin (Polfa Warszawa S.A., Warsaw, Po-
land), 100 mg/mL of streptomycin (Polfa) and 100 U/mL of
penicillin (Polfa). The Raji and HeLa cells were cultured in
Roswell Park Memorial Institute medium (RPMI-1640; Sigma-
Aldrich) with the addition of 10% (v/v) heat-inactivated FBS (Life
Technologies) and the supplements described for SK-N-MC cells
above. All cell lines were cultured under standard conditions at
37uC in a humidified atmosphere at 5% CO2 and were
subcultured every 3–4 days as required.
Proliferation Assay
The cells were seeded in 96-well plates (SK-N-MC: 1.56104
cells/well; HeLa: 5.06103 cells/well; Raji: 3.06103 cells/well;
HCT116: 3.56103 cells/well; NHDF: 3.06103 cells/well) 24 h
prior to the addition of the novel compounds. The assays were
performed using a 72 h (SK-N-MC, Raji, HeLa) or 96 h (HCT
116, NHDF) incubation period with the agents at 37uC. These
seeding and growth conditions were utilized so that the cells did
not come to confluence during the incubation periods. Addition-
ally, DFO and Dp44mT were included as positive controls in all
experiments as their activity is well characterized [21,42,50].
Chelator stock solutions were prepared in DMSO and diluted in
media so that the final [DMSO] ,0.05%. The results were
expressed as a percentage of the control and the resulting IC50
values were calculated using GraphPad Prism 5 (GraphPad
Software, Inc., La Jolla, CA, USA). The IC50 was defined as the
concentration necessary to reduce the absorbance to 50% of the
untreated control. Each individual compound was tested in
triplicate in a single experiment, with each experiment being
repeated three times. After incubation of HCT 116 and NHDF
cells with the tested compounds, 20 mL of the CellTiter 96
Aqueous One Solution - MTS (Promega, Madison, WI, USA)
solution was added to each well (with 100 mL of DMEM without
phenol red) and incubated for 1 h/37uC. The optical density of
the samples was analyzed at 490 nm.
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) was used to evaluate the anti-proliferative effects of the
chelators in SK-N-MC and Raji cells. Following incubation with
the investigated compounds, 10 mL of MTT (5 mg/mL in PBS;
Sigma-Aldrich) was added to each well. After a 2 h (SK-N-MC) or
4 h (Raji) incubation, the plates were centrifuged, and the cells
were lysed with 100 mL of 10% SDS-50% isobutanol in 0.01 M
HCl (SK-N-MC) or DMSO (Raji). The absorbance was measured
at 570 nm. The anti-proliferative effects of these novel agents on
HeLa cells were estimated using crystal violet staining (0.5%
crystal violet solution for 10 min). Finally, the wells were rinsed
with water and the cells were lysed with 2% SDS. The optical
density of the samples was analyzed at 595 nm.
Labeling of Transferrin with 59Fe
The iron transport protein, Tf (Sigma-Aldrich), was labeled with
59Fe (PerkinElmer Life and Analytical Sciences, Boston, MA) to
form 59Fe2-Tf using standard methods [6,7]. Unbound
59Fe was
removed by passage through a Sephadex G25 column and was
followed by exhaustive dialysis [6,7].
Effect of the Chelators on Mobilizing Cellular 59Fe
To examine the ability of the novel chelators to mobilize 59Fe
from SK-N-MC cells, 59Fe efflux experiments were performed
Figure 3. Synthetic route to yield the thiosemicarbazide, f.
doi:10.1371/journal.pone.0110291.g003
Figure 4. Synthetic route to yield the final thiosemicarbazones.
doi:10.1371/journal.pone.0110291.g004
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using established techniques [50,51]. The monolayer of SK-N-MC
cells was prelabeled for 3 h at 37uC in MEM containing 59Fe2-Tf
(0.75 mM). Cells were then washed four times with ice-cold PBS
and incubated for a further 3 h at 37uC with medium alone (the
control) or medium containing the chelator (25 mM). After this
incubation, the overlying medium that contained the released 59Fe
was separated from the cells using a Pasteur pipette. Radioactivity
was measured in both the cells and supernatant using a c-
scintillation counter (Wallac Wizard 3, Turku, Finland). In these
studies, the novel ligands were compared to the previously
characterized chelators, DFO and Dp44mT, as their ability to
mobilize cellular 59Fe has been extensively examined in these cells
[10,12,17,18,50].
Effect of Chelators at Preventing Cellular 59Fe Uptake
The ability of the chelators to prevent the cellular uptake of 59Fe
from 59Fe2-Tf was examined using standard methods
[10,14,17,18,50]. A monolayer of SK-N-MC cells was incubated
with medium containing 59Fe2-Tf (0.75 mM) and the chelator
(25 mM) for 3 h at 37uC. The medium was then removed and the
cells were washed four times with ice-cold PBS. The cells were
then incubated for 30 min at 4uC with the general protease,
Pronase (1 mg/mL; Sigma-Aldrich), to remove membrane-bound
59Fe. The cells were removed using a plastic spatula and
centrifuged at 14,000 rpm/1 min to separate internalized from
membrane-bound 59Fe. The cell pellet was resuspended in 1 mL
of PBS and the internalized 59Fe was measured on a c-scintillation
counter. Internalized 59Fe uptake was calculated as a percentage of
the control (medium alone). Again, the novel ligands were
compared to DFO and Dp44mT as their ability to inhibit cellular
59Fe uptake has been extensively characterized using SK-N-MC
cells [10,14,17,18,50].
Ascorbate Oxidation Assay
The ability of the iron complexes of the novel ligands to mediate
the oxidation of the physiological substrate, ascorbate, was
examined using established methods [10,18,22,52,53]. Ascorbic
acid (100 mM) was prepared immediately prior to each experiment
and was incubated in the presence of FeIII (10 mM; as FeCl3), the
chelator (1–60 mM) and a 50-fold molar excess of citrate (500 mM).
The absorbance at 265 nm was measured after 10 and 40 min and
the difference in absorbance at these time points was calculated.
The results of these experiments were expressed as iron-binding
equivalents (IBE) due to the different denticity of the chelators
examined. The chelators, Dp44mT, DFO and ethylenediamine-
tetraacetic acid (EDTA) were used as controls as the ability of their
iron complexes to oxidize ascorbate has been extensively
characterized [10,15,52,53].
Statistical Analysis
Data was expressed as mean 6S.D. of at least 3 experiments.
Statistical analyses were performed using Prism v6 (GraphPad
Software, Inc.) implementing a one-way ANOVA with Bonferro-
ni’s post-hoc test.
Results and Discussion
Drug Design
Molecular properties such as molecular weight (MW) and
calculated octanol-water partition coefficient (log Pcalc) are key
factors in the successful development of drug candidates [54,55].
In general, the average MW and log Pcalc of drugs that are
launched on the market are 300–450 Da and 2–4, respectively
[56,57]. Considering this, the clinically trialed TSC, Triapine
(MW: 195 Da; log Pcalc: 0.761), represents an interesting lead
molecule with a considerable reserve in MW and log Pcalc for
modification.
Identifying functional fragments for drug design is a complex
problem that involves different approaches, including those with
an experimental and theoretical basis. The latter consist of a
variety of methods among which are those identifying advanta-
geous sub-structures, scaffolds and/or linkers on the basis of
previously reported compounds. Alternatively, the fragmentation
of organic molecules into smaller moieties is an important method
in retrosynthetic analysis and has inspired various pseudo-retro-
synthetic approaches [58]. This has identified fragments that may
be useful for drug design. For example, the di-2-pyridyl
[12,15,21,59], quinolinyl [60], piperazinyl [60,61,62], morpholi-
nyl [63] and quinoxalinyl [64] motifs are common fragments in
other anti-cancer agents, which have been incorporated into the
design of the novel TSCs reported herein.
In the current study, the main rationale underlying our
approach was that the newly synthesized TSCs should preserve
the potent anti-cancer activity of their TSC precursors, while
retaining appropriate MW and log Pcalc values to show substantial
promise as drug candidates for pharmaceutical development. We
used a combination of retro-fragments that appear in other TSC
precursors [15,16,21,44,59] and other anti-cancer agents
[60,61,62,63,64]. Additionally, di-substitution at the terminal N4
atom was preserved through the construction of an N4-based
piperazine or morpholine ring (Fig. 5), a moiety that is observed in
several potent TSCs [45,46].
Synthesis of Novel Ligands
The thiosemicarbazide precursors, a–f (Fig. 5), were synthe-
sized from commercially available reagents in a two-step process
that gave moderate to high yields (47–95%). The treatment of
bis(imidazole)thioketone with the appropriate piperazine, followed
by the reaction with hydrazine hydrate gave the N-substituted
piperazine-based thiosemicarbazides in high yield (File S1). The
final thiosemicarbazone series, 1–6 (Fig. 5), were synthesized in
moderate to high yield (58–96%) by Schiff-base condensation of
the appropriate ketone/aldehyde with the prepared thiosemicar-
bazides. The purity of the thiosemicarbazones was confirmed by
HPLC and was .95% (see Table S2 in File S1).
Anti-Proliferative Activity of the Novel
Thiosemicarbazones Against a Variety of Cancer Cell-
Types
The ability of the novel thiosemicarbazone series 1–6 to inhibit
the cellular proliferation of tumor cells was examined in a variety
of cancer cell-types (Table 1), including human p53 wild-type and
null colon cancer (HCT116 p53+/+ and HCT116 p532/2,
respectively), Burkitt’s lymphoma (Raji), human cervical carcino-
ma (HeLa) and neuroepithelioma (SK-N-MC) cancer cells. The
ability of these novel agents to selectivity target cancer cells was
assessed by examining their effects on the cellular proliferation of a
mortal cell-type, namely normal human dermal fibroblast (NHDF)
cells. The anti-proliferative activity of series 1–6 is presented in
Table 1 and is also represented as color maps (see Fig. S4 in File
S1). The effects of these novel ligands were then compared to the
following chelators that were used as positive controls: (1) DFO,
that is clinically used for the treatment of iron overload disease
[1,3] and (2) Dp44mT, a chelator with potent anti-proliferative
activity in vitro and in vivo [15,21].
As expected from our previous studies [10,14,17,18,50], the
control chelator, DFO, demonstrated poor anti-proliferative
Anti-Cancer Activity of Novel Thiosemicarbazones
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effects in all cancer and normal cell-types, with IC50 values
ranging between 4.74 to .25 mM (Table 1). In contrast, Dp44mT
showed selective and potent anti-cancer activity with IC50 values
of 0.002–0.04 mM, but was markedly less effective in mortal
NHDF cells (IC50: 15.38 mM; Table 1).
Considering the development of new therapeutics against
cancer, it is notable that a lack of expression of the tumor
suppressor protein, p53, in some tumors aids the progression of
neoplastic cells and promotes resistance against chemotherapeutics
[65,66]. Hence, the use of agents that are active against both wild-
type and null p53 tumors are vital, particularly considering the
high prevalence of p53 mutations in advanced cancers [42,67].
Thus, we initially examined the anti-proliferative activity of the
novel TSC series 1–6 against human HCT116 p53+/+ and
HCT116 p532/2 colon cancer cells (Table 1). Significantly, the
anti-proliferative effects of most of the novel TSCs showed the
same general pattern of activity against HCT116 p53+/+ and
HCT116 p532/2 cells, irrespective of p53 status (Table 1). One
notable exception in the activity between these two cell-types was
observed for compound 3e, which showed a 100-fold decrease in
anti-proliferative efficacy when comparing HCT116 p53+/+ (IC50:
0.05 mM) and HCT116 p532/2 cells (IC50: 5 mM; Table 1).
However, overall, the anti-proliferative activity of the TSCs was
generally independent of p53 status (Table 1), as shown for other
compounds in this class [16,42]. Hence, this is an important
property of the TSCs that could explain their marked activity that
has been observed with related agents across a variety of cancer
cell-types [42].
Of all the series of TSCs synthesized in this study, those analogs
derived from di-2-pyridyl (1a–e) demonstrated the most potent
anti-proliferative activity in HCT116 p53+/+ and p532/2 cells,
resulting in IC50 values ranging from 0.0008–0.04 mM (Table 1).
While the analogs derived from quinolin-2-yl (2a–f) and 8-
hydroxyquinolin-2-yl (3a–f) demonstrated moderate anti-prolifer-
ative effects (IC50: 0.026–3.55 and 0.004–9.25 mM, respectively).
In contrast, those chelators derived from the 7-hydroxyquinolin-8-
yl (4a–f), quinoxalin-2-yl (5a–f) and salicylic (6a–f) moieties
showed poor anti-cancer activity (IC50: 1.022.25 mM) in
HCT116 p53+/+ and p532/2 cells (Table 1).
A similar general trend in the anti-proliferative activity of the
novel TSCs to those observed in HCT116 p53+/+ and p532/2
cells was also observed in Raji, HeLa and SK-N-MC cells
(Table 1). Indeed, those chelators containing the di-2-pyridyl
moiety (1a–e) were the most potent anti-cancer (IC50: 0.0003–
2.21 mM) analogs examined. Similarly to the HCT116 data,
compounds from series 2 generally displayed moderate anti-
proliferative activity (IC50: 0.04–5.14 mM) in Raji, HeLa and SK-
N-MC cells, while series 3, 4, 5 and 6 generally showed moderate
to poor anti-proliferative effects (Table 1).
Only a weak to moderate correlation (R2 = 0.01–0.6) was
evident between the anti-cancer activity of series 1–6 and their log
Pcalc values, suggesting that other factors besides their ability to
transverse the cellular membrane by passive diffusion were critical
in their anti-proliferative effects.
Anti-Proliferative Activity of the Novel
Thiosemicarbazones Against Normal, Mortal Cells
Importantly, for an agent to be useful as an anti-cancer drug, it
must show preferential anti-proliferative activity against tumor
cells over normal, mortal cell-types. Hence, the selectivity of the
novel TSCs was examined in mortal cells, namely NHDF cells. Of
all the analogs examined, 1b, 1d, 2b, 2f and 3c showed the
greatest anti-proliferative activity in the majority of cancer cell-
Figure 5. Chemical structures of the thiosemicarbazone chelators of series 1–6.
doi:10.1371/journal.pone.0110291.g005
Anti-Cancer Activity of Novel Thiosemicarbazones
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e110291
types (Table 1). Thus, to examine the selectivity of the 5 best TSCs
identified above, namely 1b, 1d, 2b, 2f and 3c, a ‘‘therapeutic
index’’ was calculated by dividing the NHDF cell IC50 by the IC50
of the neoplastic HCT116 p53+/+ or HCT116 p532/2 cell-types
(Table 2). Notably, the selectivity index of Dp44mT comparing
NHDFs to HCT116 p53+/+ or HCT116 p532/2 cell-types was
marked, being 7690 and 3076, respectively.
Of the 5 most potent anti-cancer TSCs described herein
(Table 1), the greatest therapeutic indices were identified for 1d
and 3c and were 18–2650 (Table 2). This high selectivity against
the cancer cells was due to the fact that both 1d and 3c showed
potent anti-cancer activity (IC50: 0.002–0.017 mM) in HCT116
cells, but their cytotoxicity was greatly reduced in NHDF cells
(IC50: 0.16–10.6 mM). In contrast, analogs 1b, 2b and 2f
demonstrated poor selectivity with IC50 values of 0.0008–
0.09 mM in HCT116 cells and 0.0017–0.03 mM in mortal NHDF
cells (Table 1). In fact, compounds 2b and 2f generally showed
greater anti-proliferative effects in mortal NHDF cells relative to
Table 1. Anti-proliferative activity (IC50 values) of the novel thiosemicarbazones in comparison to DFO and Dp44mT in several
tumor cell-types and normal human dermal fibroblast (NHDF) cells.
IC50 (mM)
Chelator HCT116 p53+/+ HCT116 p532/2 Raji HeLa SK-N-MC NHDF
DFO .25 .25 4.7461.80 14.3460.96 15.0665.2 .25
Dp44mT 0.00260.001 0.00560.002 0.00760.001 0.0460.01 0.01260.001 15.3865.06
1a 0.02060.002 0.04060.003 0.0860.02 0.4860.31 0.1860.09 0.01760.004
1b 0.000860.0001 0.000860.0001 0.000360.00003 0.5760.16 0.0560.01 0.001760.0007
1c 0.01460.005 0.01460.006 0.00360.004 2.2160.47 1.2160.35 0.01660.006
1d 0.00260.008 0.00960.001 0.001360.0001 0.0360.02 0.0260.01 0.1660.04
1e 0.03860.003 0.03160.003 0.0460.02 0.7260.07 0.0760.05 0.01460.003
2a 1.4460.69 3.5561.23 0.0660.02 0.4360.16 2.5460.86 9.6261.80
2b 0.04260.003 0.0960.04 0.0460.01 0.2060.07 0.3360.02 0.03360.007
2c 1.4960.02 1.5661.12 0.0660.01 1.7560.33 1.4060.69 3.2760.88
2d 0.3960.15 0.2760.16 0.0560.02 5.1462.87 0.5260.16 0.03260.008
2e 0.08860.044 0.4860.15 0.2960.11 1.5660.44 0.4860.10 9.4463.84
2f 0.02660.001 0.03560.003 0.8160.10 0.9460.45 0.8260.19 0.01560.005
3a 9.2561.42 8.8360.63 0.2060.02 3.4161.46 0.8260.61 15.864.6
3b 4.1861.46 4.6762.04 0.1960.02 8.4562.09 .6.25 8.8861.07
3c 0.00460.002 0.01760.006 0.0260.01 0.1860.07 .6.25 10.663.5
3d 8.4161.78 8.4660.25 0.1260.04 6.5960.13 .6.25 10.262.4
3e 0.0560.03 5.0162.55 0.0460.02 2.3960.02 .6.25 12.163.6
3f 3.1161.92 4.3561.35 0.0160.04 2.5760.46 .6.25 5.3661.99
4a 20.260.3 20.360.9 3.3561.11 11.361.6 5.0960.47 12.164.2
4b 7.4560.66 8.8862.53 2.2361.20 4.3860.95 4.4660.78 10.161.2
4c 20.160.3 19.864.9 3.5361.87 10.261.2 4.9760.95 .25
4d 9.1561.19 6.8465.48 1.5560.40 2.7360.55 4.5461.60 10.162.7
4e 10.160.7 9.4461.35 4.5562.52 3.4960.04 4.1761.44 9.5661.44
4f 19.060.5 18.963.6 0.4660.23 13.361.0 .6.25 9.1863.68
5a 6.1561.28 8.7261.64 0.1160.02 1.1260.03 ND 2.7361.77
5b 3.9260.74 2.2461.47 0.5060.05 6.0562.73 3.4461.12 9.6160.90
5c 2.0361.24 5.8461.65 0.2460.04 0.8660.09 2.8761.25 11.661.8
5d 9.460.8 9.4161.04 0.4960.09 1.7860.77 2.3360.09 7.1360.82
5e 5.7360.75 8.4963.05 0.2760.01 3.7761.71 1.9860.68 15.865.1
5f 1.2460.45 1.0260.54 0.7260.29 4.0962.07 2.0460.34 0.5060.21
6a .25 .25 10.266.6 22.165.4 .6.25 .25
6b 6.962.3 8.8661.46 1.9660.85 5.8060.48 5.1360.51 13.564.8
6c 15.461.7 16.463.1 3.7960.08 18.261.3 .6.25 .25
6d 9.762.5 10.661.2 2.6060.33 16.464.5 5.4260.64 18.461.9
6e 10.960.7 10.761.0 9.8362.05 19.262.5 .6.25 .25
6f .25 .25 0.6960.51 10.163.6 .6.25 .25
Results are mean 6SD (3 experiments).
doi:10.1371/journal.pone.0110291.t001
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HCT116 cells, resulting in very low therapeutic indices of 0.4–0.8
(Table 2). Compound 1b demonstrated limited selectivity and
resulted in a therapeutic index of 2 in mortal NHDF cells relative
to HCT116 cells. Hence, of all the analogs examined, compounds
1d and 3c demonstrated the greatest promise as anti-cancer
agents, having both potent and selective anti-proliferative effects.
Ability of Novel Thiosemicarbazones to Mobilize Cellular
59Fe
As the ability of chelators to bind cellular iron can play a role in
their anti-proliferative effects [50], we examined the ability of
these novel ligands (25 mM) to mobilize cellular 59Fe from
prelabeled SK-N-MC cells (Fig. 6). The chelator-mediated release
of intracellular 59Fe was compared to the positive controls, DFO
and Dp44mT (Fig. 6), as their ability to mobilize 59Fe has been
extensively characterized in these cells [10,17,18,52,53]. As
previously observed [10,17,18,52,53], the control medium alone
resulted in the release of very little 59Fe, namely 461% of cellular
59Fe (Fig. 6). The chelators, DFO and Dp44mT, significantly (p,
0.001) increased the mobilization of cellular 59Fe to 1162 and
3562%, respectively, relative to the control medium (Fig. 6).
Compounds of series 1, 3, 4 and 6 generally displayed high
efficacy at mobilizing cellular 59Fe (Fig. 6). In particular, the
ligands, 1c, 1e, 3b–3f, 4a, 4c, and 6b–6f all demonstrated
comparable 59Fe mobilization efficacy to that of Dp44mT,
resulting in the efflux of 31–39% of cellular 59Fe. Apart from
1b, all ligands of series 1, 3, 4 and 6 were significantly (p,0.001)
more effective than DFO in mediating the release of cellular 59Fe.
Interestingly, ligands of series 1 and 4 demonstrated a similar
pattern in terms of their ability to mobilize cellular 59Fe
(Fig. 6A,D). In both series 1 and 4, the ligands containing the
more hydrophilic fragments, a, c and e, showed increased efficacy
at mobilizing cellular 59Fe relative to those containing the more
lipophilic fragments b, d and f (Fig. 6A,D). Of all the ligands
examined, chelators of series 3 and 6 demonstrated the greatest
efficacy as 59Fe mobilization agents, mediating the release of 25–
39% of cellular 59Fe (Fig. 6C,F).
In contrast, the series based on quinolin-2-yl (2) and quinoxalin-
2-yl (5) generally demonstrated poor ability to mobilize cellular
59Fe and resulted in the release of 5–28% of cellular 59Fe
(Fig. 6B,E). All ligands of series 2 and 5 were significantly (p,
0.001) less effective than Dp44mT in mediating the release of
cellular 59Fe. In fact, ligand 2a demonstrated comparable 59Fe
mobilization efficacy to that of the control medium (Fig. 6B), while
2b, 2d, 2f and 5f showed comparable release of 59Fe relative to
DFO (Fig. 6B,E).
Importantly, a positive correlation (R2 = 0.911) between log
Pcalc and
59Fe mobilization efficacy was observed for ligands of
series 1 (Fig. 7), suggesting that their lipophilic/hydrophilic
balance played a role in their ability to permeate the cellular
membrane to reach intracellular 59Fe. Interestingly, the more
hydrophobic ligands of series 1 were less effective than their more
hydrophilic counterparts, suggesting that the more hydrophobic
ligands or their resultant 59Fe complexes may be sequestered in
cellular membranes, preventing 59Fe release. In contrast, a poor to
moderate correlation (R2 = 0.38–0.67) between log Pcalc and
59Fe
mobilization efficacy was evident for series 2–6. A weak
correlation (R2 = 0.37) was observed between the anti-proliferative
activity of these novel ligands and their ability to mobilize cellular
59Fe in SK-N-MC cells, indicating that other factors besides their
ability to induce 59Fe mobilization were responsible for their anti-
cancer effects.
Ability of Novel Thiosemicarbazones to Inhibit the
Cellular Uptake of 59Fe from 59Fe2-Tf
The anti-proliferative activity and iron chelation efficacy of a
ligand is dependent not only on its ability to mobilize cellular iron,
but also on its ability to prevent the cellular uptake of iron from
Fe2-Tf [50]. Thus, the ability of the novel ligands (25 mM) to
inhibit the cellular uptake of 59Fe from 59Fe2-Tf was assessed in
SK-N-MC cells (Fig. 8). As utilized in the 59Fe efflux experiments,
the chelators, DFO and Dp44mT, were included as positive
controls as their ability to inhibit 59Fe from 59Fe2-Tf has been
extensively assessed [10,14,17,18,50,52,53]. The results were
expressed as a percentage of the 59Fe uptake observed by cells
incubated with 59Fe2-Tf in control medium (i.e., in the absence of
chelator; Fig. 8).
As shown previously [10,52], DFO was able to significantly (p,
0.001) inhibit 59Fe uptake from 59Fe2-Tf to 83% of that found for
the control (Fig. 8), while Dp44mT significantly (p,0.001) and
markedly prevented the uptake of 59Fe, reducing it to 6% of the
control (Fig. 8). In general, those analogs that displayed high
efficacy at mobilizing cellular 59Fe (Fig. 6) also potently inhibited
the cellular uptake of 59Fe from 59Fe2-Tf (Fig. 8), with a linear
correlation (R2 = 0.81) evident between these 2 factors (Fig. 9).
Generally, the ligands of series 1, 3, 4 and 6 potently inhibited the
uptake of 59Fe from 59Fe2-Tf and were significantly (p,0.001)
more effective than DFO (Fig. 8A,C,D,F). In fact, the ligands, 1c,
3f, 5c, 6c and 6f demonstrated comparable inhibition of cellular
59Fe uptake to that of Dp44mT, resulting in 3.6–11.5% of cellular
59Fe uptake relative to the control (Fig. 8). Interestingly, those
Table 2. The selectivity of Dp44mT relative to the 5 most potent anti-cancer TSCs, namely 1b, 1d, 2b, 2f and 3c, was examined
by calculating their ‘‘therapeutic indices’’.
Therapeutic index
Chelator NHDF vs. HCT116 p53+/+ NHDF vs. HCT116 p532/2
Dp44mT 7690 3076
1b 2 2
1d 80 18
2b 0.8 0.4
2f 0.6 0.4
3c 2650 624
The latter was calculated by dividing the NHDF cell IC50 by the IC50 of the neoplastic HCT116 p53
+/+ or HCT116 p532/2 cell-types.
doi:10.1371/journal.pone.0110291.t002
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ligands containing the more hydrophilic fragment, c, were
generally the most effective chelators of each series (Fig. 8).
Similarly to the 59Fe efflux experiments, those ligands based on
the quinolin-2-yl (2) and quinoxalin-2-yl (5) moieties generally
showed poor ability to prevent the uptake of 59Fe from 59Fe2-Tf
(Fig. 8B,E). In fact, compound 2a showed comparable ability to
inhibit 59Fe uptake to the control medium, while compounds 2b,
2d, 2f and 5f demonstrated comparable inhibition of 59Fe uptake
to that of DFO (Fig. 8B,E). All analogs of series 2 and 5, except
5c, were significantly (p,0.001) less effective than Dp44mT at
inhibiting cellular 59Fe uptake.
No strong correlation (R2 = 0.20–0.21) was observed between
the ability of the ligands to prevent cellular 59Fe uptake and either
log Pcalc or anti-proliferative activity in SK-N-MC cells, suggesting
Figure 6. Effect of (A) series 1, (B) series 2, (C) series 3, (D) series 4, (E) series 5 and (F) series 6 chelators, relative to the controls DFO
and Dp44mT, on 59Fe mobilization from prelabeled SK-N-MC cells. Cells were incubated for 3 h/37uC with 59Fe-transferrin (0.75 mM),
washed 4 times with ice-cold PBS and then reincubated for 3 h/37uC in the presence or absence of the chelators (25 mM). Release of 59Fe was then
assessed using a c-scintillation counter. Results are mean 6SD (3 experiments).
doi:10.1371/journal.pone.0110291.g006
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other factors besides inhibition of 59Fe uptake played a role in their
anti-cancer activity.
Ability of the Iron Complexes of Novel
Thiosemicarbazones to Mediate the Oxidation of
Ascorbate
The ability of the iron complexes of the novel TSCs to catalyze
the oxidation of the physiological substrate, ascorbate, was
important to assess as redox cycling may play a critical role in
their anti-proliferative activity [10,15,18,52,53]. Thus, the oxida-
tion of ascorbate mediated by the iron complexes of series 1–6
were examined in comparison to the iron complexes of the control
compounds, DFO, EDTA and Dp44mT, as the ability of the latter
to oxidize ascorbate is well characterized [10,15,52,53,68]. The
results were expressed as a percentage of the control (no chelator)
at iron-binding equivalents (IBEs) of 0.1 (excess ‘‘free’’ iron), 1
(iron-chelator complexes with a fully filled coordination sphere), or
3 (excess free chelator), due to the different denticity of the
chelators examined (Fig. 10).
As previously observed, the redox-inactive iron complex of
DFO resulted in very limited ascorbate oxidation (Fig. 10) [15,68],
with the ligand acting in a protective manner, significantly (p,
0.05) inhibiting ascorbate oxidation at IBEs of 1 and 3 to 47% and
23% of the control, respectively (Fig. 10). In contrast, the iron
complex of the positive control, EDTA, significantly (p,0.001)
increased ascorbate oxidation at IBEs of 0.1, 1 and 3 to 208%,
449% and 936%, respectively, in comparison to the control
(Fig. 10). This is in agreement with our previous studies that
showed its ability to mediate ascorbate oxidation [10,15,52,53].
Additionally, the Dp44mT-iron complex also mediated ascorbate
oxidation, significantly (p,0.01–0.001) increasing it to 129%,
203% and 196% at IBEs of 0.1, 1 and 3, respectively, relative to
the control (Fig. 10), as demonstrated before [10,15,52,53].
The iron complexes of series 1 and 2 generally enhanced
ascorbate oxidation, with compounds 1b, 1d, 1e, 2a and 2e
significantly (p,0.05–0.001) increasing ascorbate oxidation to
200–265% of the control at an IBE of 3 (Fig. 10A,B). In fact, all
iron chelator complexes of series 1 and 2, except for 2f, showed
comparable levels of ascorbate oxidation to the Dp44mT-iron
complex at an IBE of 3 (Fig 10A,B). These data suggest that the
ligands of series 1 and 2 form iron complexes that are redox active.
In contrast to series 1 and 2, the iron complexes of series 3, 4, 5
and 6 generally did not enhance ascorbate oxidation, with the
majority acting in a protective manner (Fig. 10C,D,E,F). Although
the iron complexes of 3a and 5e mediated significantly (p,0.01–
0.001) increased levels of ascorbate oxidation, the majority of the
iron complexes of series 3, 4, 5 and 6 resulted in comparable
ability to catalyze ascorbate oxidation relative to the control at an
IBE of 3. In fact, the iron complexes of 5d, 5f, 6a, 6d and 6f
significantly (p,0.05) decreased ascorbate oxidation relative to the
control at an IBE of 3. Additionally, all iron complexes of series 3,
4, 5 and 6, apart from 3a, 4a, 4e and 5e, mediated comparable
ascorbate oxidation to that of DFO at an IBE of 3, resulting in 4–
111% of ascorbate oxidation relative to the control (Fig. 10-
C,D,E,F). Thus, the majority of iron complexes of series 3, 4, 5
and 6 acted in a protective manner, suggesting the formation of
redox inactive iron complexes.
Structure-Activity Relationships Linking Anti-Proliferative
Activity, Ascorbate Oxidation and Donor Atom Identity
In the current study, series 1 analogs based on the di-2-pyridyl
moiety (Fig. 5) generally demonstrated the greatest anti-prolifer-
ative activity of all the novel ligands examined (Table 1). Series 1
ligands, that utilize the N,N,S donor atom set, showed high iron
chelation efficacy (Figs. 6A,8A) and their iron complexes generally
resulted in the increased oxidation of ascorbate (Fig. 10A). These
data suggest that the potent anti-proliferative activity of series 1
stemmed from their ability to effectively chelate cellular iron and
result in the formation of redox active iron complexes that mediate
oxidative damage. This is in agreement with our previous studies
on other di-2-pyridyl-based thiosemicarbazones, such as Dp44mT
and DpC [12,15], and di-2-pyridyl-based thiohydrazones [52],
which also utilize the N,N,S donor atom set and demonstrate
potent anti-cancer activity via the formation of redox active
complexes. The use of ‘‘soft’’ donor atoms, such as nitrogen and
sulfur, play a critical role in facilitating reversible FeIII/II redox
cycling reactions that are important for potent anti-cancer effects
[12,15,52].
The ligands of series 2, based on the quinolin-2-yl moiety
(Fig. 5), also utilized the N,N,S donor atom set and their resultant
iron complexes generally increased levels of ascorbate oxidation
(Fig. 10B). This suggested that, similarly to series 1, ligands of
series 2 may form redox active iron complexes. However, in
contrast to series 1, series 2 compounds demonstrated poor iron
chelation efficacy, which may be a contributing factor in the
moderate anti-proliferative activity observed for series 2 relative to
series 1 (Table 1). This is consistent with our previous studies, in
which the presence of the quinolin-2-yl moiety in 2-quinoline-
carboxaldehyde isonicotinoyl hydrazones [59] and other quino-
line-based thiosemicarbazones [16] were found to have poor iron
mobilization efficacy and anti-proliferative effects in SK-N-MC
cells. Our current data support these previous findings, suggesting
that the quinolin-2-yl moiety confers poor anti-proliferative and
iron chelation efficacy when the quinoline nitrogen acts as a donor
atom [16,59].
Series 3 analogs, that differ from series 2 by the addition of a
hydroxy group at position 8 of the quinoline ring (Fig. 5), generally
demonstrated moderate to poor anti-proliferative activity (Ta-
ble 1). In contrast to series 2 that showed poor iron mobilization
efficacy and the ability to mediate ascorbate oxidation, series 3
ligands displayed high iron chelation efficacy (Figs. 6C,8C).
However, their iron complexes generally did not enhance the
oxidation of ascorbate (Fig. 10C). In fact, the majority of series 3
iron complexes acted in a protective manner and inhibited
ascorbate oxidation (Fig. 10C). It is probable that series 3 ligands
can bind iron either in a tridentate manner, using the N,N,S donor
atom set similarly to series 2, or in a bidentate system similar to
Figure 7. Relationship between the cellular iron released (%
total) and lipophilicity (logPcalc) of series 1 chelators using SK-
N-MC neuroepithelioma cells. Lines were fitted in using Microsoft
Excel 2010 (Microsoft, Redmond, WA).
doi:10.1371/journal.pone.0110291.g007
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that of the structurally-related chelator, clioquinol [69] that utilizes
the quinoline nitrogen and 8-hydroxy oxygen as donor atoms [70].
Due to the contrasting activity of series 3 relative to series 2 with
regards to anti-proliferative effects (Table 1), iron chelation
efficacy (Figs. 6&8) and ascorbate oxidation (Fig. 10), this suggests
that the series 3 analogs may act as bidentate ligands that utilize
the 8-hydroxyl oxygen and quinoline nitrogen as donor atoms.
Significantly, the use of the ‘‘hard’’ oxygen donor atom in series 3
may result in the formation of redox-inactive iron complexes that
cannot oxidize ascorbate and consequently show poor anti-
proliferative activity [1,52].
Those ligands based on the 7-hydroxyquinolin-8-yl (series 4)
moiety bind iron in an analogous manner to that of 2-
hydroxynaphthaldehyde thiosemicarbazone [71] or 2-hydroxy-1-
naphthaldehyde thiobenzoyl hydrazone (H2NTBH; [52]) and
utilize the O,N,S donor atom set [16]. Similarly, those chelators of
Figure 8. Effect of (A) series 1, (B) series 2, (C) series 3, (D) series 4, (E) series 5 and (F) series 6 chelators, relative to the controls DFO
and Dp44mT, on 59Fe uptake from 59Fe-transferrin by SK-N-MC cells. Cells were incubated for 3 h/37uC with 59Fe-transferrin (0.75 mM) in
the presence or absence of the chelators (25 mM). At the end of this incubation, cells were washed 4 times with ice-cold PBS. Internalization of 59Fe
was assessed by incubation for 30 min/4uC with the protease, Pronase (1 mg/mL). Cellular 59Fe was then assessed using a c-scintillation counter.
Results are mean 6SD (3 experiments).
doi:10.1371/journal.pone.0110291.g008
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series 6, based on the salicylic moiety, also bind iron via the O,N,S
donor atom set in a similar manner to salicylaldehyde thiobenzoyl
hydrazone (H2STBH; [52]). Although the series 4 and 6 analogs
demonstrated high iron mobilization efficacy (Figs. 6&8), these
ligands showed poor anti-proliferative effects (Table 1) and their
iron complexes did not mediate or prevented the oxidation of
ascorbate (Fig. 10). This is in agreement with our previous studies
in which the O,N,S-thiohydrazones, H2STBH or H2NTBH,
mediated high iron chelation efficacy, but showed poor anti-
proliferative activity and the inability of their iron complexes to
mediate the oxidation of ascorbate [52]. Importantly, these results
suggest that iron complexes of series 4 and 6 ligands cannot
mediate the formation of ROS, which greatly reduces their anti-
proliferative effects and this relates to the inclusion of the hard
oxygen donor (Fig. 5).
The analogs based on quinoxalin-2-yl (5a–f) utilize the N,N,S
donor atoms and differ from series 2 by an additional non-
coordinating nitrogen located at position 4 of the quinoline moiety
(Fig. 5). This structural modification resulted in a large decrease in
the anti-proliferative activity of series 5 relative to series 2
(Table 1), although both series showed poor iron mobilization
efficacy (Figs. 6&8). Importantly, the iron complexes of series 5
acted in a protective manner and inhibited the oxidation of
ascorbate, while iron complexes of series 2 were able to promote
Figure 9. Relationship between the internalized iron uptake (%
control) and cellular iron released (% total) of series 1–6 using
SK-N-MC neuroepithelioma cells. Lines were fitted in using
Microsoft Excel 2010 (Microsoft, Redmond, WA).
doi:10.1371/journal.pone.0110291.g009
Figure 10. Effect of the iron complexes of (A) series 1, (B) series 2, (C) series 3, (D) series 4, (E) series 5 and (F) series 6 chelators,
relative to DFO, Dp44mT and EDTA, on ascorbate oxidation. Chelators at iron-binding equivalent (IBE) ratios of 0.1, 1, and 3 were incubated
in the presence of FeIII (10 mM) and ascorbate (100 mM). The UV-Vis absorbance at 265 nm was recorded after 10 and 40 min, and the difference
between the time points was calculated. Results are mean 6SD (3 experiments).
doi:10.1371/journal.pone.0110291.g010
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ascorbate oxidation (Fig. 10). This further highlights the critical
role of the formation of redox active iron complexes in the anti-
proliferative activity of novel thiosemicarbazones [10,15,21,52].
Significantly, our previous studies on methyl pyrazinylketone
isonicotinoyl hydrazone (MPIH) analogs demonstrated that the
incorporation of a second, non-coordinating, electron-withdraw-
ing nitrogen in the aromatic ring played a major role in the
formation of redox-inactive iron complexes that prevented the
formation of ROS [53,72]. Similarly to series 5, the iron
complexes of the MPIH series prevented the oxidation of
ascorbate [53]. Thus, the replacement of the quinoline moiety of
series 2 with the quinoxaline group of series 5 resulted in
decreased anti-proliferative activity due to the formation of redox-
inactive iron complexes.
Conclusions
In the current study, several novel classes of TSCs were
designed that retained the appropriate MW and log Pcalc values to
show promise as drug candidates for pharmaceutical development.
A combination of retro-fragments that appear in other TSC
precursors were utilized and di-substitution at the terminal N4
atom was preserved through the incorporation of an N4-based
piperazine or morpholine ring. The selectivity and anti-cancer
activity of the novel TSCs were examined in a variety of cancer
cell-types. In particular, of all the compounds examined, 1d and
3c demonstrated the greatest promise as anti-cancer agents with
both potent and selective anti-proliferative activity (Tables 1 and
2).
Structure-activity relationship studies revealed that the combi-
nation of the donor atoms used, rather than the identity of
fragments a–f, played a crucial role in their anti-cancer activity.
Indeed, the chelators that utilized ‘‘soft’’ donor atoms, such as
nitrogen and sulfur, formed redox active iron complexes capable
of mediating ascorbate oxidation. This further highlights the
important role of ROS generation in mediating potent anti-cancer
effects. Significantly, this study identified potent and selective anti-
cancer chelators that warrant further in vivo examination.
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